Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-hodgkin lymphoma

Clinical Lymphoma, Myeloma and Leukemia

Volumn 10, Issue 4, 2010, Pages 262-269

  Lignon, Julie ^a   Sibon, David ^b,c,d   Madelaine, Isabelle ^a   Brice, Pauline ^b,c   Franchi, Patricia ^b,c   Briere, Josette ^b,c   Mounier, Nicolas ^e   Gisselbrecht, Christian ^b,c,d   Faure, Pierre ^a   Thieblemont, Catherine ^b,c,d  

^a Pharmacy Department CVS Pharmacy   (United States)

^b SAINT LOUIS HOSPITAL   (France)

^c INSERM   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

Cisplatin; Elderly patients; Neutropenia; R DHAP; Thrombocytopenia

Indexed keywords

CISPLATIN; CYTARABINE; DEXAMETHASONE; DEXCHLORPHENIRAMINE; OXALIPLATIN; PARACETAMOL; RITUXIMAB; VINCRISTINE; ANTIANEMIC AGENT; BORTEZOMIB; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER PAIN; CANCER SURVIVAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; KIDNEY FAILURE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; THROMBOCYTOPENIA; TREATMENT RESPONSE; ABDOMINAL PAIN; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CONSTIPATION; DIARRHEA; DRUG FATALITY; DRUG MEGADOSE; DRUG WITHDRAWAL; HOSPITAL READMISSION; INFECTIOUS COMPLICATION; KERATOCONJUNCTIVITIS; MORTALITY; NAUSEA; OTOTOXICITY; PERIPHERAL NEUROPATHY; PROGNOSIS; STOMATITIS; VOMITING;

EID: 77957097932     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.3816/CLML.2010.n.055     Document Type: Article

References (26)

1. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235-42.
2. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333:1540-5.
3. Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lym-phoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988; 71:117-22.
4. Hickish T, Roldan A, Cunningham D, et al. EPIC: an effective low toxicity regimen for relapsing lymphoma. Br J Cancer 1993; 68:599-604.
5. Aydin S, Duhrsen U, Nuckel H. Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients. Ann Hematol 2007; 86:271-6.
6. Thieblemont C, Gisselbrecht C. Second-line treatment paradigms for diffuse large B-cell lymphomas. Curr Oncol Rep 2009; 11:386-93.
7. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-47.
8. Chollet P, Bensmaine MA, Brienza S, et al. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol 1996; 7:1065-70.
9. Monnet I, Brienza S, Hugret F, et al. Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC). ATTIT. Association pour le Traitement des Tumeurs Intra Thoraciques. Eur J Cancer 1998; 34:1124-7.
10. Machover D, Diaz-Rubio E, de Gramont A, et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996; 7:95-8.
11. Germann N, Brienza S, Rotarski M, et al. Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patients. Ann Oncol 1999; 10:351-4.
12. Chau I, Webb A, Cunningham D, et al. An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma. Br J Haematol 2001; 115:786-92.
13. Machover D, Delmas-Marsalet B, Misra SC, et al. Dexamethasone, high-dose cy-tarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin's lymphoma. Ann Oncol 2001; 12:1439-43.
14. Sym SJ, Lee DH, Kang HJ, et al. A multicenter phase II trial of etoposide, meth-ylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin's lymphoma. Cancer Chemother Pharmacol 2009; 64:27-33.
15. Rupolo M, Spina M, Michieli M, et al. R-DHAOX as salvage regimen in patients (PTs) with relapsed/resistant non-Hodgkin's lymphoma (NHL). Blood 2004; 104: (abstract 1323).
16. Bergerat JP, Drewinko B, Corry P, et al. Synergistic lethal effect of cis-dichlo-rodiammineplatinum and 1-beta-D-arabinofuranosylcytosine. Cancer Res 1981; 41:25-30.
17. Swerdlow S, Campo E, Harris N, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Geneva, Switzerland: WHO Press; 2008.
18. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17:1244-53.
19. Vellenga E, van Putten WL, van 't Veer MB, et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood 2008; 111:537-43.
20. Mey UJ, Olivieri A, Orlopp KS, et al. DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis. Leuk Lymphoma 2006; 47:2558-66.
21. Shrestha S, Johnson C, Jain S, et al. ESHAP+/-rituximab as salvage therapy for relapsed lymphoma prior to stem cell transplant: single institution experience. Blood 2004; 104: (abstract 4601).
22. Venugopal P, Gretory SA, Showel J, et al. Rituximab (Rituxan) combined with ESHAP chemotherapy is highly active in relapsed/ refractory aggressive non-Hodgkin's lymphoma. Blood 2004; 104:(abstract 4636).
23. Hicks L, Buckstein R, Mangel J, et al. Rituximab increases response to ESHAP in relapsed, refractory, and transformed aggressive B-cell lymphoma. Blood 2006; 108: (abstract 3067).
24. Arnold C, Cuthbert R, Morris TC, et al. Rituximab-ESHAP as salvage therapy in relapsed aggressive B cell lymphoma. Haematologica 2005; 90(suppl 1): (abstract 1146).
25. Gisselbrecht C, Glass B, Mounier N, et al. R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autolo-gous stem cell transplantation: CORAL study. J Clin Oncol 2009; 27(suppl):15s (abstract 8509).
26. Yao X, Panichpisal K, Kurtzman N, et al. Cisplatin nephrotoxicity: a review. Am J Med Sci 2007; 334:115-24.